InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,187.70
(
0.13%
)
US TECH 100
17,607.60
(
-0.03%
)
Dow Jones
38,884.26
(
0.08%
)
Brent Oil
82.27
(
-0.72%
)
Bitcoin
62,241.87
(
-0.15%
)
Post# of 10797
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Bobwins

Send PM Follow Ignore
Followers 556
Posts 17434
Boards Moderated 42
Alias Born 10/21/2003

Bobwins

Re: Bobwins post# 10451

Wednesday, 09/05/2018 10:37:03 AM

Wednesday, September 05, 2018 10:37:03 AM

Post# of 10797
ATE.v/ATBPF +.04 to C$.32 Antibe closed a licensing deal with a pharma in South Korea. This is part of their strategy, signing licensing deals in non major markets to provide upfront cash while retaining the licensing to the all important North American and European markets for a potential big pharma partner.

Antibe gets 1.3 million cash up front and double digit fees once the product is developed and sold in S Korea.

https://finance.yahoo.com/news/antibe-therapeutics-announces-strategic-licensing-110000137.html?.tsrc=applewf

Please post stock symbols first in all your posts. If it's a foreign stock, please list the US pk equivalent symbol.

If the Commodities Boom is Over, I am just a Gold Bug headed for the Windshield of LIFE

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up